ENTPD5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Strongylin A (SCHEMBL8273902)	0.53	3/20
Strongylin A (SCHEMBL31536139)	0.53	3/20
SCHEMBL30628881	1.00	2/20
SCHEMBL31536076	1.00	2/20
Strongylophorine-24 (SCHEMBL31571162)	0.76	2/20
SCHEMBL12234033	0.63	2/20
SCHEMBL12234034	0.63	2/20
SCHEMBL12234038	0.63	2/20
SCHEMBL12234042	0.63	2/20
SCHEMBL10067697	0.53	2/20
SCHEMBL386764	0.51	2/20
SCHEMBL5546007	0.46	2/20
SCHEMBL10899122	0.44	2/20
SCHEMBL11705856	0.42	2/20
SCHEMBL11343263	0.41	2/20
SCHEMBL12589882	0.41	2/20
SCHEMBL11084834	0.40	2/20
SCHEMBL23597066	0.40	2/20
SCHEMBL23597165	0.40	2/20
SCHEMBL9749407	0.40	2/20

Clinical trials — most relevant to ENTPD5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)	PHASE4	UNKNOWN
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma	PHASE3	UNKNOWN
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)	PHASE1/PHASE2	RECRUITING
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer	PHASE2	RECRUITING
Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients	PHASE1/PHASE2	COMPLETED
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer	PHASE2	UNKNOWN
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers	PHASE1	COMPLETED
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer	PHASE1	COMPLETED
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients	EARLY_PHASE1	RECRUITING
CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis	nan	COMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
Genetics of Middle Ear Disease	nan	COMPLETED
A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders	nan	RECRUITING
Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia	nan	COMPLETED
PCD New Gene Discovery	nan	COMPLETED
Mucin Glycosylating Enzymes in Head and Neck Cancers	nan	UNKNOWN
Developing a Management Approach for Patients With Late-Onset Pompe Disease	nan	ACTIVE_NOT_RECRUITING
Genetic Feature of Congenital Hearing Loss in Chinese Population	nan	NOT_YET_RECRUITING
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
Pathophysiology of Paget's Disease of Bone	nan	COMPLETED
Genetic Analysis of Hereditary Disorders of Hearing and Balance	nan	COMPLETED
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
Histoblood Group Antigens as a Risk Factor of Asthma	nan	COMPLETED
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
Epigenetics, DNA Methylation Patterns and Periodontal Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ENTPD5 binder may also engage these)

Protein	Name	Similarity
E1BPW0	—	1.000	E1BPW0 →
D2GZV9	—	0.998	D2GZV9 →
Q9WUZ9	—	0.997	Q9WUZ9 →
Q6P6S9	—	0.996	Q6P6S9 →
E1C1L6	—	0.995	E1C1L6 →
Q9QYC8	—	0.989	Q9QYC8 →
Q9MYU4	—	0.985	Q9MYU4 →
P97687	—	0.982	P97687 →
O18956	—	0.982	O18956 →
O93295	—	0.981	O93295 →
P79784	—	0.979	P79784 →
Q3U0P5	—	0.978	Q3U0P5 →
O75354	—	0.978	O75354 →
P55772	—	0.977	P55772 →
Q9ER31	—	0.977	Q9ER31 →
ENTPD1	Ectonucleoside triphosphate diphosphohydrolase 1	0.976	landscape →
ENTPD3	Ectonucleoside triphosphate diphosphohydrolase 3	0.974	landscape →
O35795	—	0.968	O35795 →
Q8BFW6	—	0.966	Q8BFW6 →
Q8K0L2	—	0.965	Q8K0L2 →
Q28CF8	—	0.962	Q28CF8 →
Q5DRK1	—	0.962	Q5DRK1 →
O55026	—	0.960	O55026 →
Q9TSX8	—	0.959	Q9TSX8 →
A0JND9	—	0.959	A0JND9 →
Q58CQ9	—	0.958	Q58CQ9 →
O95498	—	0.958	O95498 →
Q9DBT4	—	0.957	Q9DBT4 →
Q5RFU0	—	0.957	Q5RFU0 →
Q9BDJ5	—	0.956	Q9BDJ5 →